GlassScriptPhysician profile
Shi Cheih Chang
NPI 1619039476
$7,447.12
in general payments reported to CMS, 2019-2025
34 companies · $840 in 2025
The $840 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $826 · 2020: $607 · 2021: $2,164 · 2022: $1,309 · 2023: $866 · 2024: $835 · 2025: $840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,540.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,459.61 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $801.23 | 2021-2025 | Repatha, Otezla |
| Amarin Pharma, INC. | $615.95 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $522.80 | 2022-2025 | |
| Lilly USA, LLC | $391.44 | 2019-2022 | |
| Emd Serono, INC. | $278.61 | 2021-2024 | Mavenclad, Mavenclad |
| Teva Pharmaceuticals USA, INC. | $244.44 | 2022-2024 | Austedo Xr |
| Abbvie INC. | $238.30 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $235.58 | 2021 | |
| Gilead Sciences, INC. | $226.32 | 2021-2025 | Vemlidy |
| Novartis Pharmaceuticals Corporation | $225.01 | 2020-2021 | |
| Eisai INC. | $217.60 | 2020-2024 | |
| Dexcom, INC. | $159.28 | 2022-2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Novo Nordisk INC | $145.82 | 2021 | |
| Neurocrine Biosciences, INC. | $131.68 | 2024 | Ingrezza |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $130.00 | 2021 | |
| Boston Scientific Corporation | $120.36 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.22 | 2019 | |
| Ucb, INC. | $120.00 | 2025 | Nayzilam |
| Lundbeck LLC | $119.56 | 2022 | |
| Sanofi-Aventis U.S. LLC | $117.39 | 2021 | |
| Conmed Corporation | $115.92 | 2024 | Airseal |
| Impel Pharmaceuticals INC. | $114.92 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $114.43 | 2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $110.71 | 2019 | |
| Amneal Pharmaceuticals LLC | $102.45 | 2025 | Crexont |
| Avanir Pharmaceuticals, INC. | $92.60 | 2021 | |
| Paratek Pharmaceuticals, INC. | $54.65 | 2020-2023 | Nuzyra |
| Merck Sharp & Dohme LLC | $27.09 | 2020-2022 | |
| Evoke Pharma, INC. | $26.96 | 2022-2023 | Gimoti |
| Phathom Pharmaceuticals, INC. | $22.39 | 2025 | Voquezna |
| Exact Sciences Corporation | $17.47 | 2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $15.17 | 2025 | Zoryve |
| Mannkind Corporation | $11.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shi Cheih Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.